The US biotech and life sciences industry has a long and proud history of driving medical innovations that have improved healthcare outcomes across a wide range of diseases and the overall quality of life for people worldwide. For too long, however, the industry’s narrative has been dominated and defined by partisans with a specific agenda … Continue reading “Drug Pricing: Innovation, Investment, and the Public Good”
Author: Johannes Fruehauf
Johannes Fruehauf is a founder and the president and executive director of LabCentral. A physician and biotech entrepreneur, prior to LabCentral he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square. He is also a co-founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits. Fruehauf earned his medical degree at the University of Frankfurt and his PhD at the University of Heidelberg (Germany).